Patents Assigned to ISIS Pharmaceuticals Inc.
  • Patent number: 9157082
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of ApoCIII mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for increasing HDL levels and/or improving the ratio of TG to HDL and reducing plasma lipids and plasma glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease or metabolic disorder, or a symptom thereof.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: October 13, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Adam Mullick, Rosanne M. Crooke, Mark J. Graham, Kenneth W. Dobie, Richard Lee
  • Publication number: 20150284725
    Abstract: Certain embodiments are directed to methods of ameliorating, treating, or preventing Kennedy's Disease in a subject carrying a mutation in the Androgen Receptor (AR) gene, such as expansion of a CAG trinucleotide repeat, which is associated with Kennedy's Disease, by administering an antisense compound targeted to AR. Several embodiments provided herein relate to the discovery that antisense compounds targeting Androgen Receptor can ameliorate, treat, or prevent Kennedy's Disease in a subject carrying a mutation in the Androgen Receptor gene, such as expansion of a CAG trinucleotide repeat, which is associated with Kennedy's Disease.
    Type: Application
    Filed: October 11, 2013
    Publication date: October 8, 2015
    Applicant: Isis Pharmaceuticals, Inc.
    Inventor: Gene Hung
  • Patent number: 9150605
    Abstract: The present invention provides compositions comprising at least one oligomeric compound comprising an alternating motif and further include a region that is complementary to a nucleic acid target. The compositions are useful for targeting selected nucleic acid molecules and modulating the expression of one or more genes. In preferred embodiments the compositions of the present invention hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. The present invention also provides methods for modulating gene expression.
    Type: Grant
    Filed: June 3, 2004
    Date of Patent: October 6, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Charles Allerson, Balkrishen Bhat, Anne B. Eldrup, Muthiah Manoharan, Richard H. Griffey, Brenda F. Baker, Eric E. Swayze
  • Patent number: 9150864
    Abstract: Disclosed herein are methods for decreasing Factor 12 and treating or preventing thromboembolic conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 12 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke, and mesenteric thrombosis. Methods for inhibiting Factor 12 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.
    Type: Grant
    Filed: November 8, 2011
    Date of Patent: October 6, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Robert A. MacLeod, Jeffrey R. Crosby
  • Patent number: 9150606
    Abstract: The present invention provides compositions comprising at least one oligomeric compound comprising an alternating motif and further include a region that is complementary to a nucleic acid target. The compositions are useful for targeting selected nucleic acid molecules and modulating the expression of one or more genes. In preferred embodiments the compositions of the present invention hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. The present invention also provides methods for modulating gene expression.
    Type: Grant
    Filed: February 9, 2005
    Date of Patent: October 6, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Charles Allerson, Balkrishen Bhat, Anne B. Eldrup, Muthiah Manoharan, Richard H. Griffey, Brenda F. Baker, Eric E. Swayze
  • Publication number: 20150275211
    Abstract: The present invention provides compounds comprising oligonucleotides complementary to a pyruvate kinase M transcript. Certain such compounds are useful for hybridizing to a pyruvate kinase M transcript, including but not limited to a pyruvate kinase M transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the pyruvate kinase M transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with cancer.
    Type: Application
    Filed: October 31, 2013
    Publication date: October 1, 2015
    Applicants: Cold Spring Harbor Laboratory, Isis Pharmaceuticals, Inc.
    Inventors: Frank Rigo, C. Bennett, Adrian R. Krainer, Zhenxun Wang
  • Publication number: 20150275208
    Abstract: The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount, activity, or expression of the target nucleic acid in a cell. In certain embodiments, hybridization results in selective modulation of the amount, activity, or expression of a target Huntingtin gene or Huntingtin transcript in a cell.
    Type: Application
    Filed: October 11, 2013
    Publication date: October 1, 2015
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Michael Oestergaard, Punit P. Seth, Eric E. Swayze
  • Patent number: 9145558
    Abstract: Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: September 29, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
  • Publication number: 20150267197
    Abstract: Disclosed herein are methods for reducing expression of C90RF72 mRNA and protein in an animal with C90RF72 specific inhibitors. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Such C90RF72 specific inhibitors include antisense compounds. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration C90RF72 specific inhibitors include amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), corticalbasal degeneration syndrome (CBD), atypical Parkinsonian syndrome, and olivopontocerellar degeneration (OPCD).
    Type: Application
    Filed: October 15, 2013
    Publication date: September 24, 2015
    Applicants: ISIS PHARMACEUTICALS, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, LUDWIG INSTITUTE FOR CANCER RESEARCH
    Inventors: C. Frank Bennett, Susan M. Freier, Frank Rigo, Don W. Cleveland, Clotilde Lagier-Tourenne, John M. Ravits, Michael W. Baughn
  • Publication number: 20150267195
    Abstract: The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell. In certain embodiments, the present invention provides compounds comprising oligonucleotides. In certain embodiments, such oligonucleotides comprise a region having a gapmer sugar motif. In certain embodiments, oligonucleotides comprise one or more type of modified sugar moieties and/or naturally occurring sugar moieties arranged along an oligonucleotide or region thereof in a defined pattern or sugar modification motif.
    Type: Application
    Filed: October 11, 2013
    Publication date: September 24, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Punit P. Seth, Susan M. Freier, Brett P. Monia, Eric E. Swayze
  • Patent number: 9139831
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing plasma lipids, plasma glucose and atherosclerotic plaques in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease or metabolic disease, or a symptom thereof.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: September 22, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham, Richard Lee, Kenneth W. Dobie
  • Publication number: 20150259681
    Abstract: The present disclosure provides tricyclic nucleosides, oligomeric compounds comprising at least one of the tricyclic nucleosides and methods of using the oligomeric compounds. The methods provided herein include contacting a cell or administering to an animal at least one of the oligomeric compounds. In certain embodiments, the oligomeric compounds hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Application
    Filed: February 20, 2015
    Publication date: September 17, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Eric E. Swayze, Andrew M. Siwkowski, Punit P. Seth, Thazha P. Prakash
  • Publication number: 20150252367
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of transthyretin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate transthyretin amyloidosis, or a symptom thereof.
    Type: Application
    Filed: May 20, 2015
    Publication date: September 10, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Brett P. Monia, Susan M. Freier, Andrew M. Siwkowski, Shuling Guo
  • Patent number: 9127278
    Abstract: Disclosed herein are antisense compounds and methods for decreasing HBV mRNA, DNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate HBV-related diseases, disorders or conditions.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: September 8, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventor: Susan M. Freier
  • Patent number: 9127033
    Abstract: The present invention provides 5? modified nucleosides and oligomeric compounds prepared therefrom. More particularly, the present invention provides modified nucleosides having at least one 5?-substituent and an optional 2? substituent, oligomeric compounds comprising at least one of these modified nucleosides and methods of using the oligomeric compounds. In some embodiments, the oligomeric compounds provided herein are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Grant
    Filed: April 26, 2011
    Date of Patent: September 8, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
  • Patent number: 9127272
    Abstract: Compounds, compositions and methods are provided for modulating the levels expression, processing and function of miRNAs. The compositions comprise oligomeric compounds targeted to small non-coding RNAs and miRNAs. The oligomeric compounds possess potent miRNA inhibitory activity, and further exhibit improved therapeutic index. Further provided are methods for selectively modulating miRNA activing in a cell.
    Type: Grant
    Filed: January 18, 2012
    Date of Patent: September 8, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Christine Esau, Eric E. Swayze, Balkrishen Bhat, Garth A. Kinberger
  • Patent number: 9127276
    Abstract: Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.
    Type: Grant
    Filed: May 1, 2014
    Date of Patent: September 8, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
  • Patent number: 9107933
    Abstract: Disclosed herein are compositions and methods for lowering Apolipoprotein C-III (ApoC-III) in a subject in need thereof. Subjects in need of ApoC-III reduction include subjects with elevated ApoC-III levels, subjects with a condition associated with ApoC-III, subjects with diabetes, obese subjects and subjects with cardiovascular disease. Compositions to lower ApoC-III include compounds targeting Apolipoprotein B (ApoB) such as Mipomersen and other antisense compound targeting ApoB.
    Type: Grant
    Filed: March 16, 2010
    Date of Patent: August 18, 2015
    Assignees: Isis Pharmaceuticals, Inc., President and Fellows of Harvard College
    Inventors: Frank M. Sacks, Diane Tribble
  • Publication number: 20150218205
    Abstract: Provided herein are methods for the solid phase synthesis of oligomeric compounds wherein at least one of the capping steps has been modified. More particularly, methods are provided wherein one or more of the capping steps is omitted or performed using reduced equivalents of acetic anhydride. In certain embodiments, the methods provide an enhanced purity profile. In certain embodiments, the methods provide an increased yield. The methods provided herein also provide at least an economic advantage over currently used methods in that reduced amounts of the mixture of capping reagents are required.
    Type: Application
    Filed: August 15, 2013
    Publication date: August 6, 2015
    Applicants: Genzyme Corporation, Isis Pharmaceuticals, Inc.
    Inventors: Isaiah E. Cedillo, Darren Janczak, Phillip Michael Weaver
  • Patent number: 9096851
    Abstract: This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds.
    Type: Grant
    Filed: June 25, 2012
    Date of Patent: August 4, 2015
    Assignees: Excaliard Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc.
    Inventors: Nicholas M. Dean, J. Gordon Foulkes, Niall O'Donnell, C. Frank Bennett, Susan M. Frier